In a report released today, Jeff Johnson from Robert W. Baird upgraded Dexcom (DXCM – Research Report) to a Buy, with a price target of ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $95.91, ...

Fintel reports that on January 16, 2025, Baird upgraded their outlook for DexCom (NasdaqGS:DXCM) from Neutral to Outperform.

In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target ...

We recently compiled a list of the 10 Firms Shine Amid Wall Street’s Lackluster Trading. In this article, we are going to ...

DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher. Gross ...

Buoyed by the recent launch of Stelo and further upcoming CGM launches, Dexcom is anticipating a 14% growth in 2025 over 2024 ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...

Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a ...

DexCom (DXCM) shares rise 6% premarket after setting financial forecast for 2025, projecting 14% revenue growth over 2024 on ...

Chase Coleman III is the founder of Tiger Global Management. Coleman’s hedge fund is a whale with nearly $56 billion in ...